Key Points
- EVP Gianluca Pettiti sold 400 shares on Feb. 9 at an average of $541.20 for $216,480, leaving him with 20,752 shares — a 1.89% reduction in his ownership.
- Thermo Fisher shares were reported trading down ~2.5%; the stock recently opened at $526.56 with a market cap of about $197.8B, a 52-week range of $385.46–$643.99, and 50/200-day moving averages of $588.09 and $544.22.
- The company beat Q4 estimates (EPS $6.57 vs. $6.45; revenue $12.22B vs. $11.95B), announced a $5.0B buyback (~2.4% of shares), and analysts have raised price targets (consensus ~$633.68, mostly Buy ratings).
Thermo Fisher Scientific Inc. (NYSE:TMO - Get Free Report) EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $541.20, for a total value of $216,480.00. Following the completion of the transaction, the executive vice president directly owned 20,752 shares in the company, valued at $11,230,982.40. This represents a 1.89% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Thermo Fisher Scientific Trading Down 2.5%
NYSE TMO opened at $526.56 on Thursday. The firm has a market capitalization of $197.83 billion, a price-to-earnings ratio of 29.68, a PEG ratio of 3.11 and a beta of 0.93. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.53 and a current ratio of 1.89. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $643.99. The company's 50 day moving average price is $588.09 and its 200 day moving average price is $544.22.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Thursday, January 29th. The medical research company reported $6.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.45 by $0.12. The company had revenue of $12.22 billion during the quarter, compared to analyst estimates of $11.95 billion. Thermo Fisher Scientific had a net margin of 15.05% and a return on equity of 16.92%. The business's quarterly revenue was up 7.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $6.10 earnings per share. On average, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.
Thermo Fisher Scientific declared that its board has approved a stock repurchase plan on Thursday, November 6th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to repurchase up to 2.4% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company's board of directors believes its stock is undervalued.
Institutional Trading of Thermo Fisher Scientific
Several hedge funds and other institutional investors have recently bought and sold shares of TMO. High Note Wealth LLC increased its holdings in shares of Thermo Fisher Scientific by 170.6% in the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company's stock valued at $27,000 after acquiring an additional 29 shares during the last quarter. JPL Wealth Management LLC acquired a new position in Thermo Fisher Scientific in the third quarter worth $28,000. Highline Wealth Partners LLC raised its holdings in shares of Thermo Fisher Scientific by 126.9% during the third quarter. Highline Wealth Partners LLC now owns 59 shares of the medical research company's stock worth $29,000 after purchasing an additional 33 shares during the period. Beacon Financial Strategies CORP bought a new position in shares of Thermo Fisher Scientific in the 4th quarter worth about $29,000. Finally, Olistico Wealth LLC acquired a new stake in Thermo Fisher Scientific during the fourth quarter worth about $29,000. 89.23% of the stock is owned by institutional investors.
Analysts Set New Price Targets
Several research firms recently commented on TMO. Stifel Nicolaus boosted their price target on Thermo Fisher Scientific from $583.00 to $700.00 and gave the stock a "buy" rating in a research report on Friday, January 9th. Leerink Partners raised their price target on shares of Thermo Fisher Scientific from $545.00 to $580.00 and gave the company an "outperform" rating in a report on Wednesday, October 22nd. Citigroup boosted their price objective on shares of Thermo Fisher Scientific from $660.00 to $685.00 and gave the stock a "buy" rating in a report on Friday, January 30th. The Goldman Sachs Group began coverage on Thermo Fisher Scientific in a research report on Tuesday, December 9th. They set a "buy" rating and a $685.00 target price on the stock. Finally, KeyCorp raised Thermo Fisher Scientific from a "sector weight" rating to an "overweight" rating and set a $750.00 price target for the company in a report on Sunday, December 7th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and two have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $633.68.
Check Out Our Latest Analysis on TMO
Thermo Fisher Scientific Company Profile
(
Get Free Report)
Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.
Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
